Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nano-silymarin
- Development stage
- Unknown
- Lead developer
- Exir Nano Sina
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Nano-silymarin is a nanomicellar formulation of silymarin, a polyphenolic flavonoid extract derived from milk thistle (*Silybum marianum*). Silymarin is composed of active flavonolignans, primarily silybin, silydianin, and silychristin, which possess potent antioxidant, anti-inflammatory, and anti-apoptotic properties. Due to the poor oral bioavailability of natural silymarin, nano-sizing (reducing particles to 1–100 nm) or nanomicellar encapsulation is utilized to enhance absorption and cellular delivery. Nano-silymarin is being investigated for various therapeutic applications, including the prevention of chemotherapy-induced bone marrow suppression, hand-foot syndrome, neuropathy, and hepatotoxicity, as well as vancomycin-induced nephrotoxicity, COVID-19, and multiple sclerosis (MS) as an immunomodulatory adjunct to stem cell therapies.
- Brand names
- SinalivSinalive
- Other names
- nanomicelle silymarinsilymarin nanomicelles
02
Targets
NF-κBNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on nano-silymarin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nano-silymarin.